Univariate analysis for prognostic factors affecting overall survival
| Variable . | Unfavorable factors . | Hazard ratio (95% CI) . | P . |
|---|---|---|---|
| B symptoms | Positive | 2.67 (1.14-6.24) | .024 |
| Age | > 60 y | 2.43 (1.46-4.06) | .001 |
| Clinical stage | III/IV | 2.22 (1.33-3.72) | .002 |
| Extranodal involvement | > 1 site | 2.13 (1.28-3.54) | .003 |
| LDH | > normal | 1.87 (1.13-3.10) | .015 |
| Sex | Female | 1.43 (0.91-2.27) | .12 |
| PS | 2-4 | 0.82 (0.51-1.33) | .43 |
| Necrosis | Presence | 2.98 (1.55-5.73) | .001 |
| CD20 positivity | > 50% | 2.43 (1.19-4.98) | .015 |
| Background CTL | Increase* | 1.86 (0.94-3.68) | .074 |
| Variable . | Unfavorable factors . | Hazard ratio (95% CI) . | P . |
|---|---|---|---|
| B symptoms | Positive | 2.67 (1.14-6.24) | .024 |
| Age | > 60 y | 2.43 (1.46-4.06) | .001 |
| Clinical stage | III/IV | 2.22 (1.33-3.72) | .002 |
| Extranodal involvement | > 1 site | 2.13 (1.28-3.54) | .003 |
| LDH | > normal | 1.87 (1.13-3.10) | .015 |
| Sex | Female | 1.43 (0.91-2.27) | .12 |
| PS | 2-4 | 0.82 (0.51-1.33) | .43 |
| Necrosis | Presence | 2.98 (1.55-5.73) | .001 |
| CD20 positivity | > 50% | 2.43 (1.19-4.98) | .015 |
| Background CTL | Increase* | 1.86 (0.94-3.68) | .074 |
CI indicates confidence interval; LDH, lactate dehydrogenase; PS, performance status; and CTL, cytotoxic T cell.
More than 30% of cytotoxic T cells among background lymphocytes.